Drug Target Review

MARCH 4, 2025

Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. In this interview, Bagnall explains how this approach is improving patient outcomes and driving the development of better obesity drugs. Mark is an entrepreneur and business manager in the healthcare industry.

Therapies 52

Therapies Treatment Clinical Trials Science 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR. star.edu.sg.

Licensing 52

Licensing Licensing Therapies Science 52

Drug Target Review

NOVEMBER 25, 2024

I started my career with a degree in biomedical sciences from the University of East Anglia in Norwich, UK. I went on to complete my MBA and PhD at The Institute of Cancer Research (ICR) in drug development. Personally, I went from working in licensing and business development in big pharma straight to being a CEO.

Treatment 52

Treatment Small Molecule Clinical Trials Trials 52

The Pharma Data

JANUARY 31, 2021

–( BUSINESS WIRE )– Gilead Sciences, Inc. While HIV treatment has advanced dramatically over the past three decades, people living with HIV still face a lifetime of therapy,” said Diana Brainard, MD, Senior Vice President, Virology Therapeutic Area, Gilead Sciences. About Gilead Sciences. Gilead Sciences, Inc.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

Advarra

AUGUST 10, 2023

Given the relatively small populations affected by any one rare disease or condition, a pharmaceutical company developing an orphan drug may reasonably expect the final approved drug to generate relatively small sales (when compared with the drug development costs) and consequently incur a financial loss.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Drug Target Review

JULY 6, 2023

History behind animal testing In December 2022, the US Government approved the ground-breaking US Food and Drug Association (FDA) Modernization Act 2.0, 3 The first act was approved in 1938 in response to a drug — elixir sulphanilamide — that caused 105 deaths after researchers failed to test the antibiotic before release.

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Molecule Blog

JANUARY 9, 2023

IP-NFTs and Decentralized, Autonomous Science Today, most science is conducted at centralized institutions with a high barrier to entry and a reliance on imprecise human labor. Research is built on data (and sometimes code) that routinely isn’t shared, affecting our ability to replicate science.

Research 52

Research Licensing Licensing Science 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Together, these nine companies have collectively developed more than 70 novel vaccines that have helped to eradicate some of the world’s most complex and deadly public health threats, underscoring their experience in clinical development and regulatory rigor, as well as their longstanding commitments to patient safety and public health.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

FDA Law Blog: Drug Discovery

FEBRUARY 2, 2023

While this hype may be warranted in some respects—a 60-year old legal provision has now been amended to acknowledge that the science of drug development is advancing—the change is mostly symbolic and is likely to take many years before we see it have a measurable impact. 42 U.S.C. § 262(k)(2)(A)(i)(I).

Animal Testing 64

Animal Testing Biosimilars Cell Based Assays FDA 64

Perficient: Drug Development

SEPTEMBER 19, 2023

More information will be available in the coming weeks. Expanded Partnerships Google Salesforce and Google are expanding their partnership to further integrate their products.

Licensing 59

Licensing Licensing Production Marketing 59

DrugBank

OCTOBER 4, 2024

This involves assessing the strength and breadth of patents, evaluating the potential for future patent challenges, and analyzing the value derived from licensing agreements and royalty streams. The high costs associated with bringing a new drug to market, estimated to be over $2.6

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 129

Therapies Virus DNA Clinical Trials 129

NIH Director's Blog: Drug Development

FEBRUARY 27, 2018

More than 90 percent of that contributory research was basic—that is, related to the discovery of fundamental biological mechanisms, rather than actual development of the drugs themselves. Previous attempts to quantify the contribution of federal funding to new drug development had looked primarily at patents.

Research 52

Research Science FDA Pharmaceutical Companies 52

Agency IQ

MAY 31, 2024

The legislation further explained that for a certain method to qualify as a “platform technology,” it must demonstrate “reasonable likelihood to bring significant efficiencies to drug development and review processes.” based on a letter of authorization from the application holder).” which would never be acceptable.

Science 40

Science FDA Production Licensing 40

NIH Director's Blog: Drug Development

JUNE 14, 2016

Several years ago, the Food and Drug Administration (FDA) recommended that drug developers take special care to show that potential drugs to treat diabetes don’t adversely affect the cardiovascular system [1]. In fact, the evidence suggests that such drugs might even offer some protection against heart disease.

Drugs 52

Drugs Disease Drug Development Clinical Trials 52

Codon

SEPTEMBER 29, 2024

While mRNA data was often illuminating, their interpretation was tricky; more akin to art than science. It wasn’t a silver bullet to the hard problem of drug development, but it wasn’t too far off either. Models of life became the dominant research paradigm in nearly every life-sciences field.

Engineering 141

Engineering Virus DNA Therapies 141

DrugBank

DECEMBER 4, 2024

   The Economics of Drug Access   The economics of drug access is a complex interplay of factors, including research and development (R&D) costs, manufacturing and distribution costs, intellectual property rights (IPR), pricing policies, and healthcare financing mechanisms.

Drugs 52

Drugs Licensing Licensing Pharmaceutical Companies 52

Perficient: Drug Development

JANUARY 24, 2024

With that being said, I’ve had a lot of experience with healthcare companies, both payers, providers and life sciences organizations dealing with HIPAA regulations over the last decade and having seen the direction Sitecore has been moving to support healthcare companies, I wanted to share some of that knowledge and information.

Licensing 96

Licensing Licensing Production Regulations 96

LifeSciVC

JANUARY 25, 2024

Challenges in drug discovery and development It is not easy moving new science and technology platforms forward. Translation of this novel science in the industry setting is just as daunting. And so the effort required to successfully commercialize a drug in the U.S. Drug approvals kept pace during this time.

Science 72

Science Clinical Trials Trials Medical Schools 72

Agency IQ

MAY 3, 2024

Title Type Comments Close Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards Draft Guidance April 30 Early Alzheimer’s Disease: Developing Drugs for Treatment Draft Guidance May 13 Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the (..)

FDA 40

FDA Science Regulations Clinical Trials 40

Agency IQ

AUGUST 2, 2024

The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Biosimilars 40

The Pharma Data

JUNE 28, 2021

The companies acquired by Bayer, Noria and PSMA Therapeutics, have exclusive world-wide rights to technology licensed from Weill Cornell Medicine (New York, NY, USA) and Johns Hopkins University (Baltimore, MD, USA). Noria was founded by Dr. John Babich, Chief, Radiopharmaceutical Sciences in Radiology at Weill Cornell Medicine.

Small Molecule 52

Small Molecule Licensing Licensing Therapies 52

Agency IQ

JUNE 2, 2023

The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

JANUARY 12, 2021

Marianne De Backer, Head of Business Development & Licensing in Bayer’s Pharmaceuticals Division, pictured above. We want them to focus on their science and make sure they keep their entrepreneurial culture,” De Backer said, describing the company as a “docking station” for its subsidiaries and partners.

Therapies 52

Therapies Licensing Licensing Pharmaceuticals 52

Molecule Blog

AUGUST 19, 2021

In drug development however, when a therapeutic is discovered, or research becomes more akin to product development, the source of funding must change. These grants are utilised by researchers to get to the point of developing a potentially life-saving therapeutic. And this is the best-case scenario. for patents)?

Research 52

Research Licensing Licensing Drug Development 52

The Pharma Data

NOVEMBER 1, 2020

The program is based on pioneering science from INSERM, CNRS, Aix Marseille University and the University of Bordeaux , and is being developed in collaboration with REGENXBIO Inc. In addition, Corlieve has licensed REGENXBIO’s NAV AAV9 technology for the TLE program. Maryland , US), a leading gene therapy company.

Therapies 52

Therapies Science Treatment Disease 52

LifeSciVC

JULY 17, 2024

By Mike Cloonan, Chief Executive Officer of Sionna Therapeutics, as part of the From The Trenches feature of LifeSciVC The drug development process in rare diseases is rife with challenges especially when companies target significant differentiation or first-in-class targets.

Clinical Research 69

Clinical Research Disease Research Clinical Trials 69

Agency IQ

JULY 22, 2024

All products are received in one of two forms: A New Drug Application (or NDA, for pharmaceuticals) or a Biologics License Application (BLA, for biologics). Novel drug products are defined as products that have never been approved for any indication.

Clinical Trials 52

Clinical Trials Trials Science FDA 52

The Pharma Data

DECEMBER 20, 2020

Food and Drug Administration (FDA) is plenty busy with COVID-19 vaccine Emergency Use Authorizations (EUAs) this month, but they’re also wrapping up the year with a few PDUFA dates for other therapies. Urovant Sciences’ Vibegron for Overactive Bladder. Here’s a look. and Europe, including Russia.

FDA 52

FDA FDA Approval Licensing Licensing 52

Agency IQ

JUNE 29, 2023

The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

Agency IQ

SEPTEMBER 29, 2023

The following PDUFA dates were obtained from publicly available sources.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

JANUARY 13, 2021

14, 2021 /PRNewswire/ — MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow , an accomplished pharmaceutical executive, as Chief Development Officer. We are excited to attract such top tier talent from the psychedelic drug development community.

Clinical Trials 52

Clinical Trials FDA Trials Production 52

LifeSciVC

JANUARY 16, 2024

Rise of the best-in-class biologics plays: Are you looking to in-license or invest in “de-risked” biology that is already in the clinic? Whether trial design, execution, or otherwise, drug development even where there is precedent is a challenging road and should not be taken for granted. Join the club.

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Target Review

SEPTEMBER 19, 2024

Could you give us an overview of IRLAB’s current drug development pipeline? According to IRLAB’s calculations, the probability that an ISP-generated drug will reach pivotal Phase III studies is almost three times higher than for a drug developed with traditional methods – 20 percent compared to seven percent.

Disease 52

Disease Drugs Treatment Drug Development 52

The Pharma Data

DECEMBER 29, 2020

Its drug development pipeline includes thymus, pancreas, and kidney regeneration. is a life sciences company developing therapies to modify aging — increasing human health span and longevity. LyGenesis’s lead allogeneic cell therapy program is focused on liver regeneration for patients with end stage liver disease.

Therapies 40

Therapies FDA Trials Disease 40